MX348738B - Cepa huesped bacteriana que expresa dsbc recombinante. - Google Patents
Cepa huesped bacteriana que expresa dsbc recombinante.Info
- Publication number
- MX348738B MX348738B MX2014000302A MX2014000302A MX348738B MX 348738 B MX348738 B MX 348738B MX 2014000302 A MX2014000302 A MX 2014000302A MX 2014000302 A MX2014000302 A MX 2014000302A MX 348738 B MX348738 B MX 348738B
- Authority
- MX
- Mexico
- Prior art keywords
- bacterial host
- host strain
- expressing recombinant
- strain expressing
- recombinant dsbc
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
La presente invención se refiere a una célula bacteriana gram-negativa recombinante que comprende un vector de expresión, que comprende un polinucleótido que codifica DsbC y uno o más polinucleótidos que codifican un anticuerpo o un fragmento de unión al antígeno del mismo especialmente de unión a CD154. Una célula E. coli bacteriana gram-negativa recombinante, caracterizada porque comprende: a) un vector de expresión que comprende un polinucleótido recombinante que codifica DsBC; b) un gen Tsp mutado que codifica una proteína Tsp que tiene 50% o menos de actividad de proteína o proteica en comparación con una célula de tipo silvestre; c) un gen spr mutante que codifica una proteína spr que resulta en un cambio del aminoácido cisteína a alanina en la posición 94 (C94A) de acuerdo con la SEX ID NO: 26; y d) uno o más polinucleótidos que codifican un anticuerpo o un fragmento de unión al antígeno del mismo que se une específicamente a CD154.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11173880 | 2011-07-13 | ||
| PCT/EP2012/002945 WO2013007388A1 (en) | 2011-07-13 | 2012-07-13 | Bacterial host strain expressing recombinant dsbc |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014000302A MX2014000302A (es) | 2014-02-17 |
| MX348738B true MX348738B (es) | 2017-06-27 |
Family
ID=46545736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014000302A MX348738B (es) | 2011-07-13 | 2012-07-13 | Cepa huesped bacteriana que expresa dsbc recombinante. |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9725516B2 (es) |
| EP (2) | EP2731973B1 (es) |
| JP (3) | JP6431370B2 (es) |
| KR (1) | KR102023786B1 (es) |
| CN (1) | CN103649124B (es) |
| AU (1) | AU2012283388B2 (es) |
| BR (1) | BR112013032871B1 (es) |
| CA (1) | CA2841824C (es) |
| CY (1) | CY1119985T1 (es) |
| DK (1) | DK2731973T3 (es) |
| EA (1) | EA031449B1 (es) |
| ES (1) | ES2659155T3 (es) |
| HK (1) | HK1194393A1 (es) |
| HR (1) | HRP20180226T1 (es) |
| HU (1) | HUE035674T2 (es) |
| IL (1) | IL229947B (es) |
| IN (1) | IN2014DN00202A (es) |
| LT (1) | LT2731973T (es) |
| ME (1) | ME02957B (es) |
| MX (1) | MX348738B (es) |
| NO (1) | NO2731973T3 (es) |
| PL (1) | PL2731973T3 (es) |
| PT (1) | PT2731973T (es) |
| RS (1) | RS56926B1 (es) |
| SG (1) | SG10201807560XA (es) |
| SI (1) | SI2731973T1 (es) |
| WO (1) | WO2013007388A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2125894T3 (pl) * | 2007-03-22 | 2019-08-30 | Biogen Ma Inc. | Białka wiążące, w tym przeciwciała, pochodne przeciwciał i fragmenty przeciwciał, które swoiście wiążą się z CD154 i ich zastosowania |
| EP2993231B1 (en) | 2009-09-24 | 2018-08-01 | UCB Biopharma SPRL | Bacterial strain for recombinant protein expression, having protease deficient degp retaining chaperone activity, and knocked out tsp and ptr genes |
| GB201000587D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201000590D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
| GB201000591D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201012599D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
| JP6431370B2 (ja) * | 2011-07-13 | 2018-11-28 | ユセベ ファルマ ソシエテ アノニム | 組換えＤｓｂＣを発現する細菌宿主系統 |
| GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
| GB201223276D0 (en) * | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| BR112017013394B1 (pt) | 2014-12-22 | 2024-02-06 | Ucb Biopharma Sprl | Método para fabricar proteína de interesse |
| KR101810778B1 (ko) * | 2015-06-23 | 2017-12-20 | 서울대학교산학협력단 | Cd154 결합 폴리펩타이드 및 그 용도 |
| WO2017132298A1 (en) | 2016-01-27 | 2017-08-03 | Medimmune, Llc | Methods for preparing antibodies with a defined glycosylation pattern |
| KR20210090645A (ko) * | 2018-11-05 | 2021-07-20 | 제넨테크, 인크. | 원핵 숙주 세포에서 2개의 사슬 단백질을 생산하는 방법 |
| CN109371049A (zh) * | 2018-11-14 | 2019-02-22 | 天津大学 | 分子伴侣在促进单克隆抗体的形成和/或提高单克隆抗体的表达量中的应用 |
| WO2020188350A1 (en) | 2019-03-18 | 2020-09-24 | Bio-Rad Abd Serotec Gmbh | Protection of spytag-containing periplasmic fusion proteins from protease tsp and ompt degradation |
| EP4010500A1 (de) * | 2019-08-05 | 2022-06-15 | Wacker Chemie AG | Bakterienstamm zur freisetzung eines rekombinanten proteins in einem fermentationsverfahren |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
| US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| AU4118393A (en) | 1992-04-28 | 1993-11-29 | Regents Of The University Of Michigan, The | Human crabp-I and crabp-II |
| GB9215540D0 (en) | 1992-07-22 | 1992-09-02 | Celltech Ltd | Protein expression system |
| US5304472A (en) | 1992-11-20 | 1994-04-19 | Genentech, Inc. | Method of controlling polypeptide production in bacterial cells |
| US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US6027888A (en) | 1996-04-05 | 2000-02-22 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
| JP2000083670A (ja) | 1998-09-09 | 2000-03-28 | Hsp Kenkyusho:Kk | ＤｓｂＡ／ＤｓｂＢ／ＤｓｂＣ／ＤｓｂＤ発現プラスミド |
| EP1190258B1 (en) | 1999-06-29 | 2006-10-25 | Siga Technologies, Inc. | Assay for degp protease inhibitors |
| GB0006398D0 (en) | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| AU8867501A (en) | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| WO2002018446A2 (en) | 2000-09-01 | 2002-03-07 | Biogen, Inc. | Methods of designing and producing compounds having improved binding affinity for cd154 or other trimeric proteins |
| US7041479B2 (en) | 2000-09-06 | 2006-05-09 | The Board Of Trustess Of The Leland Stanford Junior University | Enhanced in vitro synthesis of active proteins containing disulfide bonds |
| EP1356052B1 (en) * | 2000-12-14 | 2008-08-20 | Genentech, Inc. | Production of full antibodies in procaryotic cells |
| BR0116680A (pt) | 2000-12-14 | 2005-04-05 | Genentech Inc | Linhagem de e. coli e método de produção de um polipeptìdeo |
| TWI334439B (en) | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| CN100513414C (zh) | 2001-08-27 | 2009-07-15 | 杰南技术公司 | 进行抗体表达和装配的系统 |
| GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
| SG148848A1 (en) | 2001-11-16 | 2009-01-29 | Biogen Idec Inc | Polycistronic expression of antibodies |
| GB0129105D0 (en) * | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
| AU2003244817B2 (en) | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| AU2003287345A1 (en) | 2002-10-31 | 2004-06-07 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| PT1570267E (pt) | 2002-12-03 | 2012-01-03 | Ucb Pharma Sa | Ensaio para a identificação de células produtoras de anticorpos |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| CA2528551A1 (en) | 2003-06-13 | 2005-01-13 | Biogen Idec Ma Inc. | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
| CN1845938B (zh) | 2003-06-30 | 2010-05-26 | 杜门蒂斯有限公司 | 多肽 |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| CA2533593A1 (en) | 2003-07-26 | 2005-02-10 | Biogen Idec Ma Inc. | Altered antibodies having improved antigen-binding affinity |
| MX2007001015A (es) | 2004-07-26 | 2007-04-12 | Biogen Idec Inc | Anticuerpos anti-cd154. |
| CA2577082A1 (en) * | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| GB0425534D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Process for obtaining antibodies |
| GB0520169D0 (en) | 2005-10-04 | 2005-11-09 | Celltech R&D Ltd | Biological products |
| PL2125894T3 (pl) | 2007-03-22 | 2019-08-30 | Biogen Ma Inc. | Białka wiążące, w tym przeciwciała, pochodne przeciwciał i fragmenty przeciwciał, które swoiście wiążą się z CD154 i ich zastosowania |
| JP5592792B2 (ja) | 2007-09-26 | 2014-09-17 | ユセベ ファルマ ソシエテ アノニム | 二重特異性抗体の融合体 |
| US7662587B1 (en) | 2009-03-05 | 2010-02-16 | E. I. Du Pont De Nemours And Company | Gene knockout mutations that increase peptide production |
| EP2993231B1 (en) | 2009-09-24 | 2018-08-01 | UCB Biopharma SPRL | Bacterial strain for recombinant protein expression, having protease deficient degp retaining chaperone activity, and knocked out tsp and ptr genes |
| US8470552B2 (en) | 2009-10-12 | 2013-06-25 | Keck Graduate Institute | Strategy to reduce lactic acid production and control PH in animal cell culture |
| US8361744B2 (en) | 2009-11-05 | 2013-01-29 | Genentech, Inc. | Methods and composition for secretion of heterologous polypeptides |
| GB201000588D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
| GB201000587D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201000591D0 (en) * | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
| GB201000590D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
| GB201001791D0 (en) | 2010-02-03 | 2010-03-24 | Ucb Pharma Sa | Process for obtaining antibodies |
| GB201012599D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
| JP6431370B2 (ja) | 2011-07-13 | 2018-11-28 | ユセベ ファルマ ソシエテ アノニム | 組換えＤｓｂＣを発現する細菌宿主系統 |
| EP2546267A1 (en) | 2011-07-13 | 2013-01-16 | UCB Pharma S.A. | Bacterial host strain expressing recombinant DsbC |
| GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
-
2012
- 2012-07-13 JP JP2014519454A patent/JP6431370B2/ja active Active
- 2012-07-13 HU HUE12737492A patent/HUE035674T2/en unknown
- 2012-07-13 CN CN201280034512.9A patent/CN103649124B/zh active Active
- 2012-07-13 SI SI201231206T patent/SI2731973T1/en unknown
- 2012-07-13 WO PCT/EP2012/002945 patent/WO2013007388A1/en active Application Filing
- 2012-07-13 EA EA201490274A patent/EA031449B1/ru not_active IP Right Cessation
- 2012-07-13 EP EP12737492.4A patent/EP2731973B1/en active Active
- 2012-07-13 RS RS20180171A patent/RS56926B1/sr unknown
- 2012-07-13 BR BR112013032871-1A patent/BR112013032871B1/pt active IP Right Grant
- 2012-07-13 ME MEP-2018-33A patent/ME02957B/me unknown
- 2012-07-13 ES ES12737492.4T patent/ES2659155T3/es active Active
- 2012-07-13 AU AU2012283388A patent/AU2012283388B2/en active Active
- 2012-07-13 NO NO12737492A patent/NO2731973T3/no unknown
- 2012-07-13 SG SG10201807560XA patent/SG10201807560XA/en unknown
- 2012-07-13 DK DK12737492.4T patent/DK2731973T3/da active
- 2012-07-13 KR KR1020137034718A patent/KR102023786B1/ko active IP Right Grant
- 2012-07-13 EP EP17196968.6A patent/EP3339325A1/en not_active Withdrawn
- 2012-07-13 PT PT127374924T patent/PT2731973T/pt unknown
- 2012-07-13 IN IN202DEN2014 patent/IN2014DN00202A/en unknown
- 2012-07-13 MX MX2014000302A patent/MX348738B/es active IP Right Grant
- 2012-07-13 PL PL12737492T patent/PL2731973T3/pl unknown
- 2012-07-13 CA CA2841824A patent/CA2841824C/en active Active
- 2012-07-13 LT LTEP12737492.4T patent/LT2731973T/lt unknown
- 2012-07-13 US US14/131,994 patent/US9725516B2/en active Active
-
2013
- 2013-12-17 IL IL22994713A patent/IL229947B/en active IP Right Grant
-
2014
- 2014-07-30 HK HK14107814.3A patent/HK1194393A1/zh unknown
-
2017
- 2017-08-03 US US15/667,649 patent/US9957328B2/en active Active
- 2017-10-31 JP JP2017209932A patent/JP2018019719A/ja active Pending
-
2018
- 2018-02-06 HR HRP20180226TT patent/HRP20180226T1/hr unknown
- 2018-02-15 CY CY20181100192T patent/CY1119985T1/el unknown
-
2019
- 2019-11-01 JP JP2019200029A patent/JP7062626B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX348738B (es) | Cepa huesped bacteriana que expresa dsbc recombinante. | |
| GB201000588D0 (en) | Bacterial host strain | |
| CY1118990T1 (el) | Βακτηριακο στελεχος ξενιστης που εκφραζει ανασυνδυασμενη dsbc και εχει μειωμενη ενεργοτητα tsp | |
| NZ762662A (en) | Anti-pd-l1 antibody and uses thereof | |
| MX2020009692A (es) | Moleculas biespecificas de union a antigeno activadoras de celulas t. | |
| CY1122978T1 (el) | Αντισωματα εναντι-vla-4 | |
| MX2015010843A (es) | Moleculas biespecificas de union al antigeno que activan celulas t. | |
| MX2014005546A (es) | Anticuerpos de union de albumina y fragmentos de union de los mismos. | |
| WO2014200910A3 (en) | Bioinformatic processes for determination of peptide binding | |
| MX2015010350A (es) | Moleculas de union a antigeno biespecificas que activan la celula t. | |
| PH12016500275A1 (en) | Antibodies | |
| WO2014005683A8 (en) | Dna vaccine for use in pancreatic cancer patients | |
| AU2012298537A8 (en) | Bispecific T cell activating antigen binding molecules | |
| MX2015013181A (es) | Anticuerpos humanos pac1. | |
| WO2013173706A3 (en) | Huwentoxin-iv variants and methods of use | |
| MY192757A (en) | Anti-ccl17 antibodies | |
| EA201491034A1 (ru) | Экспрессионная кассета |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |